Prostate Cancer, Recurrent Prostate Cancer
Conditions
Keywords
11C-choline, Positron Emission Tomography, 15-117
Brief summary
The purpose of this study is to use a new imaging drug called 11C-choline that is used with a PET/CT scan to see prostate cancer when it cannot be seen well on other scans, such as bone scans, CT or MRI.
Interventions
DRUG11C-choline
DEVICEPET/CT Scan
Sponsors
Memorial Sloan Kettering Cancer Center
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient must have biopsy-proven adenocarcinoma of the prostate initially treated with curative intent (surgery and radiation therapy are most common treatments but other treatments are also eligible). * Biochemical recurrence defined as any of the following: 1. PSA ≥ 0.2 ng/mL in at least two sequential tests for patients treated with surgery. 2. PSA ≥ 0.2 ng/mL above the post therapy nadir for patients treated with radiation therapy, brachytherapy or cryotherapy. 3. PSA ≥ 0.2 ng/ml above the most recent therapy nadir for patients who have received additional treatment in the recurrent setting * Patient must have undergone standard-of-care restaging that does not clearly identify site(s) of active disease, or such prior studies must show equivocal findings for which further work-up is considered necessary to make clinical decision. Standard staging examinations may include one or more of the following: CT or MRI, bone imaging (either Tc-99m bisphosphonate scintigraphy MDP or F-18 sodium fluoride PET), FDG PET, or In-111 capromab pendetide scintigraphy no older than 3 months of consent date. * Age ≥ 18 years. * Patient must be able to tolerate PET/CT imaging. * Patient must be able to understand and willing to sign a written informed consent document.
Exclusion criteria
* Patient must not have claustrophobia that would preclude PET/CT imaging or other contraindications to CT imaging.
Countries
United States
Outcome results
None listed